Novartis

The latest development could significantly reshape India’s cardiac drugs market

First malaria drug for babies approved; set for rollout in Africa within weeks

Until now, infants were treated with medications intended for older children, which posed a risk of overdose because babies metabolize drugs differently due to their immature liver function

Trump Tariff – How much can it hurt Indian pharma?

The first order impact will be a slow market share gain from innovators after a generic launch

Divi's Labs shares fall nearly 3% as US court says Novartis cannot block generic of best-selling heart drug

Divi's Labs has a CDMO contract with Novartis for Entresto

Alkem Labs in talks to acquire Novartis AG's India unit: CNBC-TV18

The total value of the deal is likely to be around Rs 2,000 crore, the channel said

Novartis raises guidance after beating Q1 expectations

It expects its 2024 net sales to grow by a high-single to low double-digit percentage with adjusted operating income growing by a low double-digit to mid-teens percentage, Novartis said in a statement.

Dr. Reddy's eyeing to acquire Novartis' India arm: Report

Novartis India, a listed entity, is set to undergo an assessment encompassing various aspects, including its parent Novartis AG's 70.68% shareholding.

Novartis to acquire cancer-centric MorphoSys for $2.9 billion

MorphoSys secured pelabresib, with a $1.7 billion takeover from U.S. cancer specialist Constellation Pharma, in the hopes of setting a new treatment standard.

World Street | China's market restrictions, Novartis' M&A bid, Yandex's Russia exit, Estee Lauder's jobs cuts and more

From Chinese regulator's new restrictions and Bank of Japan's plans to shift gears to Invitae's bankruptcy woes and Novartis' mega acquisition bid,here's a look at some of the major developments from across the world.

JB Pharma inks Rs 964-cr licence deal with Novartis for ophthalmology brands

As per IQVIA, MAT September, 2023 data, sales for these brands was at Rs 207.8 Crores.

We invest 20% of our revenue towards overall research including cancer: Novartis India MD

"We are looking at new therapies of cell therapy, radioisotopes for cancer treatment. 20 percent of our revenue goes as investment towards cancer treatment. We have 30 compounds in the pipeline towards treatment of cancer," Novartis India MD Amitabh Dube said.

Fit to Lead | Novartis India’s Amitabh Dube: ‘Focus keeps you on the right track, discipline helps you to be consistent’

Challenge for 2024: The Novartis India country president and MD will prioritise personal health and wellness. And embrace FOMO, making peace with the fact that one can't always be in the know.

Novartis to buy Chinook for up to $3.5 billion in boost to late-stage pipeline

The transaction, in the form of a merger of a newly formed Novartis subsidiary and Chinook, is expected to close in the second half of 2023, the Swiss drugmaker said in a statement.

Global pharma companies pushing to innovate in India: OPPI president

The industry body says it is collaborating, converging and co-creating with the government and other stakeholders to enable an innovative environment in India

Cipla inks licensing pact with Novartis for diabetes drug

The Mumbai-based company has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) to manufacture and market Galvus and Galvus combination brands, it said in a regulatory filing.

Novartis launches new $11 billion share buyback

The Swiss company said it will buy a maximum of 10% of its own stock over the period from its last Annual General Meeting, which took place on March 7, up to the AGM in 2026.

Novartis, Eli Lilly get court notices in case related to breast cancer drugs

The Kerala High Court said the drugmakers are parties to a petition seeking generic versions of their patented products to lower treatment costs.

Novartis CEO on how yoga & lessons from his grandparents help him take big professional decisions

Novartis’ global CEO Vas Narasimhan finds solace in his Indian heritage when he has to gather the courage to make a tough decision in life, even on a professional level. Catch this exclusive conversation between Novartis CEO Vas Narasimhan and CNBC-TV18's managing editor Shereen Bhan to find out why he appreciates his grandparents for teaching him yoga and what he thinks about the increasing number of Indian-origin CEOs.

How yoga since childhood days helped this Indian-origin CEO

Vasant Narasimhan, the Indian-origin CEO of pharmaceutical giant Novartis, credits yoga and meditation for giving him courage and strength in tough times

‘Indian-origin CEOs take pride in identity’: Novartis’s Vas Narasimhan

In an exclusive interview with CNBC-TV18, Novartis top boss Vas Narasimhan spoke about the rise and rise of Indian-origin CEOs.

Novartis global chief focuses on innovative medicines for Indian market

These diseases are prevalent in India and other developing countries, and Novartis sees a significant market opportunity in providing innovative treatments, Narasimhan said.

MC Analysis I Why India’s cardiology pharma market is expecting a major disruption this year

With a blockbuster heart failure drug Vymada going off-patent this month, its much cheaper generic versions by a number of drug makers are set to hit the market in India and several other countries. 

Glenmark generics for heart failure drug to lower cost by up to 126%

The drug by Glenmark, under the brand name Sacu VTM, has been priced at Rs 19 per tablet for a dose of 50mg , Rs 35 per tablet for a dose of 100mg and Rs 45 per tablet for a dose of 200mg

US Supreme Court rebuffs Novartis, allows generic versions of MS drug

Novartis had asked the justices to suspend a lower court's ruling that lifted a ban on generic versions of Gilenya, the Switzerland-based company's third highest-selling drug last year with $2.8 billion in sales.

Novartis to spin off generics business Sandoz next year

Novartis (NOVN.S) announced on Thursday that it intended to spin off its generics division Sandoz in order to narrow its focus on its patented prescription drugs.